Brokerages expect that Opko Health Inc. (NASDAQ:OPK) will announce earnings of ($0.09) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Opko Health’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.10). Opko Health posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 35.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 5th.
On average, analysts expect that Opko Health will report full year earnings of ($0.36) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.32). For the next year, analysts expect that the business will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.40) to ($0.26). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Opko Health.
A number of equities analysts have recently issued reports on OPK shares. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. ValuEngine upgraded shares of Opko Health from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Piper Sandler upped their target price on shares of Opko Health from to in a research report on Tuesday, March 10th. Finally, Barrington Research reiterated a “buy” rating and set a $4.00 target price on shares of Opko Health in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $2.88.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Great West Life Assurance Co. Can acquired a new position in Opko Health during the fourth quarter valued at approximately $35,000. 360 Financial Inc. acquired a new stake in Opko Health in the fourth quarter worth $47,000. Sowell Financial Services LLC acquired a new stake in Opko Health in the fourth quarter worth $59,000. Alpine Global Management LLC bought a new position in shares of Opko Health during the fourth quarter worth $61,000. Finally, Hollencrest Capital Management bought a new position in shares of Opko Health during the fourth quarter worth $65,000. Institutional investors and hedge funds own 26.28% of the company’s stock.
Shares of OPK stock traded up $0.02 during trading hours on Monday, reaching $1.40. 11,474,535 shares of the company were exchanged, compared to its average volume of 31,235,914. Opko Health has a fifty-two week low of $1.33 and a fifty-two week high of $2.91. The stock’s fifty day moving average is $1.63 and its two-hundred day moving average is $1.68. The company has a market cap of $924.36 million, a price-to-earnings ratio of -2.64 and a beta of 1.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.30 and a quick ratio of 1.09.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Further Reading: Insider Trading – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.